Prognostication of anaplastic astrocytoma patients: application of contrast leakage information of dynamic susceptibility contrast-enhanced MRI and dynamic contrast-enhanced MRI.

摘要: To examine the applicability of contrast leakage information from dynamic susceptibility contrast-enhanced (DSC) MRI and (DCE) to determine which one is most valuable surrogate imaging biomarker for predicting disease progression in anaplastic astrocytoma (AA) patients. This study was approved by institutional review board (IRB), waived informed consent. A total seventy-three AA patients who had undergone preoperative DCE DSC received standard treatment, including partial resection or biopsy followed radiation therapy, were included this retrospective study. Based on Response Assessment Neuro-Oncology (RANO), sorted into (n = 21) non-progression 52) groups. Tumor boundaries defined as high-signal intensity (SI) lesions fluid-attenuated inversion recovery (FLAIR) imaging, where we analyzed mean pharmacokinetic parameters (Ktrans, Vp, Ve) (mean extraction fraction (EF)) MRI. Mean Ve EF significantly higher with progression-free survival (PFS) < 18 months than those PFS ≥ 18 months. For distinguishing group months, AUC values calculated using value (AUC 0.716). The Kaplan-Meier analysis revealed that correlated PFS. In Cox proportional-hazards regression, only found be associated We based high-SI tumor FLAIR capable outcomes a potential biomarker. • Ve(2.152 ± 1.857 vs. 1.173 1.408) (p 0.02). regression showed Ve(p 0.034) PFS, regardless IDH mutation status,